
Hansa Biopharma - Continuous progress is temporarily blurred by true-up

Hansa's launch progress continues in Q2. The net sales include provisions reflecting an extended period of "true-up" relating to the effect of European sales and volume discounts and refunds pertaining to historical and recent sales. We can expect some future provisions or true-up revisions as volume increases, but these provisions are likely to fade at a later stage of the European launch advances. Our Base Case remains SEK 120 with a Bull Case of SEK 220 and a Bear Case of SEK 15.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Hansa Biopharma - Continuous progress is temporarily blurred by true-up](#)